Patients with prostate cancer continue to have excess mortality up to 15 years after diagnosis

Olga Husson, Liza N. van Steenbergen, Evert L. Koldewijn, Philip M. Poortmans, Jan Willem W. Coebergh, Maryska L. G. Janssen-Heijnen

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Objective
To estimate the population-based conditional 5-year relative survival rates for patients with prostate cancer (PCa).
Patients and Methods
All 98 672 patients, aged 45–89 years, diagnosed in the Netherlands with PCa (clinical T stage 1–4) in the period 1989–2008 were selected from the Netherlands Cancer Registry and followed up until 2010.The conditional 5-year relative survival rate was estimated for every subsequent year of survival up to 15 years after diagnosis.
Results
The conditional 5-year relative survival rate decreased with survival time from diagnosis. Excess mortality (conditional 5-year relative survival rate <95%) for patients with clinical T1 stage only became manifest 5 years after diagnosis and increased to almost 10% after 10 years.Patients with more advanced disease (cT2–cT4) were found to have an excess mortality rate of 6–12% at diagnosis, which increased to 15–22% after 10 years.Excess mortality occurred earlier for the older age groups.The 5-year relative survival rate at diagnosis was <90% for all age groups of patients with cT3/cT4 disease and excess mortality for this group increased to >20% for those who had already survived for 5 years since diagnosis.
Conclusions
Patients with PCa were found to have excess mortality within 10 years of diagnosis. Excess mortality was found at an earlier timepoint for patients with a more advanced stage and for older age groups.Quantitative insight into conditional survival is useful for caregivers to help plan optimum cancer treatment and surveillance and to inform patients about their actual prognosis during follow-up, taking the current condition of the patient into account.
Original languageEnglish
Pages (from-to)691-697
JournalBJU International
Volume114
Issue number5
DOIs
Publication statusPublished - 2014

Keywords

  • conditional survival
  • long-term prognosis
  • population-based
  • prostate cancer
  • cancer registry

Cite this

Husson, O., van Steenbergen, L. N., Koldewijn, E. L., Poortmans, P. M., Coebergh, J. W. W., & Janssen-Heijnen, M. L. G. (2014). Patients with prostate cancer continue to have excess mortality up to 15 years after diagnosis. BJU International, 114(5), 691-697. https://doi.org/10.1111/bju.12519
Husson, Olga ; van Steenbergen, Liza N. ; Koldewijn, Evert L. ; Poortmans, Philip M. ; Coebergh, Jan Willem W. ; Janssen-Heijnen, Maryska L. G. / Patients with prostate cancer continue to have excess mortality up to 15 years after diagnosis. In: BJU International. 2014 ; Vol. 114, No. 5. pp. 691-697.
@article{3c4e67c8bb6c4cf885663f51600068c3,
title = "Patients with prostate cancer continue to have excess mortality up to 15 years after diagnosis",
abstract = "ObjectiveTo estimate the population-based conditional 5-year relative survival rates for patients with prostate cancer (PCa).Patients and MethodsAll 98 672 patients, aged 45–89 years, diagnosed in the Netherlands with PCa (clinical T stage 1–4) in the period 1989–2008 were selected from the Netherlands Cancer Registry and followed up until 2010.The conditional 5-year relative survival rate was estimated for every subsequent year of survival up to 15 years after diagnosis.ResultsThe conditional 5-year relative survival rate decreased with survival time from diagnosis. Excess mortality (conditional 5-year relative survival rate <95{\%}) for patients with clinical T1 stage only became manifest 5 years after diagnosis and increased to almost 10{\%} after 10 years.Patients with more advanced disease (cT2–cT4) were found to have an excess mortality rate of 6–12{\%} at diagnosis, which increased to 15–22{\%} after 10 years.Excess mortality occurred earlier for the older age groups.The 5-year relative survival rate at diagnosis was <90{\%} for all age groups of patients with cT3/cT4 disease and excess mortality for this group increased to >20{\%} for those who had already survived for 5 years since diagnosis.ConclusionsPatients with PCa were found to have excess mortality within 10 years of diagnosis. Excess mortality was found at an earlier timepoint for patients with a more advanced stage and for older age groups.Quantitative insight into conditional survival is useful for caregivers to help plan optimum cancer treatment and surveillance and to inform patients about their actual prognosis during follow-up, taking the current condition of the patient into account.",
keywords = "conditional survival, long-term prognosis, population-based, prostate cancer, cancer registry",
author = "Olga Husson and {van Steenbergen}, {Liza N.} and Koldewijn, {Evert L.} and Poortmans, {Philip M.} and Coebergh, {Jan Willem W.} and Janssen-Heijnen, {Maryska L. G.}",
year = "2014",
doi = "10.1111/bju.12519",
language = "English",
volume = "114",
pages = "691--697",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "5",

}

Husson, O, van Steenbergen, LN, Koldewijn, EL, Poortmans, PM, Coebergh, JWW & Janssen-Heijnen, MLG 2014, 'Patients with prostate cancer continue to have excess mortality up to 15 years after diagnosis', BJU International, vol. 114, no. 5, pp. 691-697. https://doi.org/10.1111/bju.12519

Patients with prostate cancer continue to have excess mortality up to 15 years after diagnosis. / Husson, Olga; van Steenbergen, Liza N.; Koldewijn, Evert L.; Poortmans, Philip M.; Coebergh, Jan Willem W.; Janssen-Heijnen, Maryska L. G.

In: BJU International, Vol. 114, No. 5, 2014, p. 691-697.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Patients with prostate cancer continue to have excess mortality up to 15 years after diagnosis

AU - Husson, Olga

AU - van Steenbergen, Liza N.

AU - Koldewijn, Evert L.

AU - Poortmans, Philip M.

AU - Coebergh, Jan Willem W.

AU - Janssen-Heijnen, Maryska L. G.

PY - 2014

Y1 - 2014

N2 - ObjectiveTo estimate the population-based conditional 5-year relative survival rates for patients with prostate cancer (PCa).Patients and MethodsAll 98 672 patients, aged 45–89 years, diagnosed in the Netherlands with PCa (clinical T stage 1–4) in the period 1989–2008 were selected from the Netherlands Cancer Registry and followed up until 2010.The conditional 5-year relative survival rate was estimated for every subsequent year of survival up to 15 years after diagnosis.ResultsThe conditional 5-year relative survival rate decreased with survival time from diagnosis. Excess mortality (conditional 5-year relative survival rate <95%) for patients with clinical T1 stage only became manifest 5 years after diagnosis and increased to almost 10% after 10 years.Patients with more advanced disease (cT2–cT4) were found to have an excess mortality rate of 6–12% at diagnosis, which increased to 15–22% after 10 years.Excess mortality occurred earlier for the older age groups.The 5-year relative survival rate at diagnosis was <90% for all age groups of patients with cT3/cT4 disease and excess mortality for this group increased to >20% for those who had already survived for 5 years since diagnosis.ConclusionsPatients with PCa were found to have excess mortality within 10 years of diagnosis. Excess mortality was found at an earlier timepoint for patients with a more advanced stage and for older age groups.Quantitative insight into conditional survival is useful for caregivers to help plan optimum cancer treatment and surveillance and to inform patients about their actual prognosis during follow-up, taking the current condition of the patient into account.

AB - ObjectiveTo estimate the population-based conditional 5-year relative survival rates for patients with prostate cancer (PCa).Patients and MethodsAll 98 672 patients, aged 45–89 years, diagnosed in the Netherlands with PCa (clinical T stage 1–4) in the period 1989–2008 were selected from the Netherlands Cancer Registry and followed up until 2010.The conditional 5-year relative survival rate was estimated for every subsequent year of survival up to 15 years after diagnosis.ResultsThe conditional 5-year relative survival rate decreased with survival time from diagnosis. Excess mortality (conditional 5-year relative survival rate <95%) for patients with clinical T1 stage only became manifest 5 years after diagnosis and increased to almost 10% after 10 years.Patients with more advanced disease (cT2–cT4) were found to have an excess mortality rate of 6–12% at diagnosis, which increased to 15–22% after 10 years.Excess mortality occurred earlier for the older age groups.The 5-year relative survival rate at diagnosis was <90% for all age groups of patients with cT3/cT4 disease and excess mortality for this group increased to >20% for those who had already survived for 5 years since diagnosis.ConclusionsPatients with PCa were found to have excess mortality within 10 years of diagnosis. Excess mortality was found at an earlier timepoint for patients with a more advanced stage and for older age groups.Quantitative insight into conditional survival is useful for caregivers to help plan optimum cancer treatment and surveillance and to inform patients about their actual prognosis during follow-up, taking the current condition of the patient into account.

KW - conditional survival

KW - long-term prognosis

KW - population-based

KW - prostate cancer

KW - cancer registry

U2 - 10.1111/bju.12519

DO - 10.1111/bju.12519

M3 - Article

VL - 114

SP - 691

EP - 697

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 5

ER -

Husson O, van Steenbergen LN, Koldewijn EL, Poortmans PM, Coebergh JWW, Janssen-Heijnen MLG. Patients with prostate cancer continue to have excess mortality up to 15 years after diagnosis. BJU International. 2014;114(5):691-697. https://doi.org/10.1111/bju.12519